Clinical Chemistry Analyzers Market Share Analysis Report, 2024-2033
The global clinical chemistry analyzers market size was exhibited at USD 18.73 billion in 2023 and is projected to hit around USD 28.18 billion by 2033, growing at a CAGR of 4.17% during the forecast period 2024 to 2033.
The U.S. clinical chemistry analyzers market size was valued at USD 8.18 Billion in 2023 and is expected to grow from USD 8.54 Billion in 2024 to reach USD 12.58 billion by 2033, at a CAGR of 4.4% during the forecast period (2024-2033)
North America dominated the market with the revenue share of 35.16% in 2023, due to rising healthcare spending in country, such as the U.S. The healthcare infrastructure in the U.S. is well established, which has led to a huge adoption rate for clinical chemistry and reagents in laboratories and hospitals. Moreover, favorable healthcare reimbursement scenarios in such regions have also motivated greater penetration of automated chemistry analyzers.
The U.S. dominated the North America market in 2023 due to including the growing adoption of analyzers in healthcare settings, continuous technological advancements, and the presence of key market players. Some of the key market players include Beckman Coulter, Elitech Group, Horiba Ltd., Johnson & Johnson, Mindray Medical International Ltd., Ortho-Clinical Diagnostics, and Siemens AG. In July 2023 , Siemens Healthineers Atellica CI Analyzer received FDA clearance and is now available in major markets worldwide, marking its official launch, which is expected to boost the regional market growth. Additionally, the growing geriatric population in the U.S. is contributing to the market's growth, as the elderly population is more likely to require diagnostic tests and services.
Asia Pacific region is anticipated to grow at the fastest CAGR during the forecast period owing to the presence of a large target population and increasing penetration of leading clinical chemistry product manufacturers in countries, such as India and China. Furthermore, high R&D investment by the global players and the presence of unexplored opportunities in this region serve as high growth rendering drivers.
Japan's dominance in the Asia Pacific market is attributed to the high demand for diagnostic reagents and devices, driven by the largest aging population in the world. The increasing prevalence of chronic diseases and the need for advanced diagnostic solutions have contributed to the growth of this market in Japan. F. Hoffmann-La Roche is the leading manufacturer of clinical chemistry analyzers in Japan, further underlining the country's importance in this market.
| Report Coverage | Details |
| Market Size in 2024 | USD 19.51 Billion |
| Market Size by 2033 | USD 28.18 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 4.17% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Product, Test, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Thermo Fisher Scientific, Inc.; Danaher Corporation (Beckman Coulter); Abbott, Siemens Healthineers AG; F. Hoffmann-La Roche Ltd; Horiba, Ltd.; ELITech Group; QuidelOrtho Corporation; Randox Laboratories Ltd. |
The increasing prevalence of chronic diseases, such as diabetes, is predicted to be one of the high-impact rendering drivers of this market. This subsequent increase in disease prevalence has triggered companies to produce advanced clinical chemistry solutions at a large scale, to aid in diagnosis.
Consequently, the high need for clinical chemistry products led to unprecedented growth in new market entrants, resulting in high competition.
The technological innovations in clinical chemistry products have led to early disease detection and specialized diagnosis in the areas of oncology, gynecology, & endocrinology and enabled testing on a larger scale. The advancements comprise better resolution, advanced modeling & parameter estimation, computer-assisted interpretation, improved pattern recognition, and artificial intelligence (AI).
The benefits of the abovementioned advancements and automated analyzers are automatic data acquisition, greater process control allowing real-time automation, efficient parameter monitoring, and automatic variable adjustment. These tools also offer analysis of a wide range of samples and facilitate immediate generation of results, reflecting their potential use in the intensive care unit, outpatient clinics, and emergency as well as surgical wards in the future. These benefits are estimated to drive physician preference for these solutions, thus creating high potential opportunities for growth during the forecast period.
However, one of the major restraints for laboratories, hospitals, and manufacturers in global market is the high capital investments required for these instruments which will lead to high cost of the tests, decreased affordability, and will increased the exit and entry barrier for new entrants. However, various steps are being taken to decrease the initial setup cost such as reagent rental agreements and cost-per-test which will help in a significant reduction of cost and help in growth of the market. Also, limited investments and reimbursements for these diagnostic tests and availability of cheaper diagnostic methods are expected to hinder the growth of the market.
The market is currently experiencing a high growth stage, with an accelerating pace of expansion. This market is marked by innovation driven by technological advancements, including advanced analysis techniques. The continuous evolution in clinical chemistry analyzers is giving rise to applications, unsettling traditional approaches, and fostering the emergence of new paradigms within the healthcare industry.
The market is also characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. For instance, in July 2023 , Canon Medical Systems acquired Minaris Medical, including its subsidiaries. This move aims to enhance Canon Medical's in vitro diagnostics business by leveraging synergies between reagent technology and automated biochemical analyzer technology.
The market is also subject to increasing regulatory scrutiny. The regulatory challenges include the need to comply with stringent regulatory guidelines and quality standards. This includes implementing processes and procedures for design, manufacturing, and testing to ensure the safety and effectiveness of the analyzers.
There are a limited number of direct product substitutes for clinical chemistry analyzers. However, there are a number of substitutes for clinical chemistry analyzers including point-of-care testing devices, alternative diagnostic methods, emerging technologies such as biosensors, other laboratory analyzers, and traditional laboratory techniques depending on specific diagnostic needs and preferences.
The market sees a high degree of geographical expansion strategies, with key players such as HORIBA and Thermo Fisher Scientific employing this approach to broaden their service reach. This strategy enhances service availability across diverse geographic areas, ensuring a more extensive market presence. For instance, in September 2023 , HORIBA UK expanded its clinical chemistry portfolio with the POINTE G6PD Assay Kit for detecting Glucose-6-phosphate dehydrogenase deficiency. This enzymatic test, acquired from Pointe Scientific, streamlines G6PD testing with its 5-minute lysing step and compatibility with HORIBA's clinical chemistry analyzers. The addition aligns with HORIBA's strategy of enhancing its IVD market offerings.
Based on product, the reagents segment led the market with the largest revenue share of 57.4% in 2023. The substantial share is predicted to be a consequence of a wide array of reagents present in the market, catering to different requirements of clinicians. These reagents predominantly include enzymes, substrates, specific proteins, electrolytes, lipids, and others, which are imperative to obtain accurate results in analytical procedures. In addition, reagents are believed to be highly cost efficient, and possess optimum sensitivity, linearity, and precision, which thereby ensures minimized performance variation. The aforementioned benefits are predicted to be highly responsible for encouraging clinicians to use reagents for accurate diagnosis.
The analyzers segment is expected to grow the fastest CAGR over the forecast period, owing to the wide product range and extensive utilization in diagnosis of chronic diseases. Moreover, technological advancements and high R&D expenditure have resulted in development of advanced analyzers which offer advantages such as better resolution, quick diagnosis, improved point of care testing capabilities, computer assisted interpretation, and others. The above-mentioned advantages are expected to boost the analyzers market over the forecast period.
Based on the test type, the basic metabolic panel (BMP) segment held a market with the largest revenue share of 29.56% in 2023, owing to growing prevalence of lifestyle-induced diseases, such as obesity and other metabolic abnormalities. Rising importance of and awareness regarding point-of-care testing is also one of the key contributing factors toward the segment share. BMP comprises a set of tests that provide clinical information pertaining to problems caused by a chemical imbalance in the body to the medical examiners.
The associated benefits with this test have resulted in the high acceptance of the same, thereby widening the segment share over the years. Moreover, BMP is increasingly being used and accepted in a wide array of applications, such as in newborn screening, which facilitates early detection of congenital genetic as well as metabolic disorders. According to a research paper published in NCBI, it possesses the ability to detect 30 inherited metabolic disorders in a single dried filter paper blood spot.
Based on end-use, the hospitals segment led the market in 2023 with the largest revenue share of 58.42%, owing to the high patient volume, frequent readmissions, and large sample volumes. Moreover, supportive infrastructure facilitates successful diagnostic procedures, thus resulting in a higher share of hospitals. The increasing number of government initiatives aimed at promoting efficient diagnostic facilities to generate quick results and improve overall efficiency also serves as key contributing factors to the substantial share of the segment.
In addition, in the current scenario, hospitals are increasingly inclined toward acquiring fully automated systems with built-in quality-assurance capabilities, possessing the ability to process a large number of samples. These factors are estimated to exert positive influence on segment growth. The diagnostic laboratories segment is expected to grow at fastest CAGR over the forecast period. Automated analyzers enhance efficiency, reducing turnaround times. Increasing public awareness fosters proactive health monitoring, amplifying diagnostic test volumes. Governments' emphasis on accurate diagnostics and healthcare infrastructure investments propel the adoption of advanced clinical chemistry analyzers. These factors collectively drive the growth of the segment during the forecasted period
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global clinical chemistry analyzers market.
Product
Test
End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers